Literature DB >> 8080043

Osteopontin expression and distribution in human carcinomas.

L F Brown1, A Papadopoulos-Sergiou, B Berse, E J Manseau, K Tognazzi, C A Perruzzi, H F Dvorak, D R Senger.   

Abstract

Osteopontin (OPN), a secreted adhesive glycoprotein, is significantly overexpressed in a variety of experimental models of malignancy. Moreover, increased levels of OPN have been detected in the blood of patients with metastatic carcinoma. To investigate OPN expression and distribution in human carcinomas directly, we studied a wide variety of common tumors by Northern analysis, in situ hybridization, and immunohistochemistry. All 14 tumors studied by Northern analysis showed very substantial increases in OPN messenger (m)RNA when compared to corresponding normal tissues. Moreover, intense labeling for OPN mRNA was detected in 71 of 76 carcinomas studied by in situ hybridization. In most of the carcinomas studied (colon, stomach, duodenum, pancreas, breast, lung, bladder, prostate, ovary, thyroid, and melanoma), tumor cells did not label detectably for OPN mRNA; however, macrophages intimately associated with tumor cells labeled strongly for the OPN transcript. In carcinomas of the kidney and endometrium, both tumor cells and host macrophages labeled strongly for OPN mRNA. The presence of OPN mRNA in macrophages was particularly pronounced at the edge of tumors (ie, the tumor/stroma interface) and in areas of tumor necrosis. Although in most cases tumor cells did not label detectably for OPN mRNA, both tumor cells and macrophages stained for OPN protein, suggesting that OPN secreted by macrophages may bind to tumor cells, possibly through the glycine-arginine-glycine-aspartate-serine cell binding domain in OPN. Collectively, these data suggest that OPN functions in adhesive interactions at the tumor/host interface and thereby may influence processes such as invasion and metastasis.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8080043      PMCID: PMC1890312     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  30 in total

1.  Recognition of osteopontin and related peptides by an alpha v beta 3 integrin stimulates immediate cell signals in osteoclasts.

Authors:  A Miyauchi; J Alvarez; E M Greenfield; A Teti; M Grano; S Colucci; A Zambonin-Zallone; F P Ross; S L Teitelbaum; D Cheresh
Journal:  J Biol Chem       Date:  1991-10-25       Impact factor: 5.157

2.  Transformation-specific secreted phosophoproteins.

Authors:  D R Senger; D F Wirth; R O Hynes
Journal:  Nature       Date:  1980-08-07       Impact factor: 49.962

3.  Cloning and sequence analysis of rat bone sialoprotein (osteopontin) cDNA reveals an Arg-Gly-Asp cell-binding sequence.

Authors:  A Oldberg; A Franzén; D Heinegård
Journal:  Proc Natl Acad Sci U S A       Date:  1986-12       Impact factor: 11.205

4.  Characterization of a cDNA for chicken osteopontin: expression during bone development, osteoblast differentiation, and tissue distribution.

Authors:  M A Moore; Y Gotoh; K Rafidi; L C Gerstenfeld
Journal:  Biochemistry       Date:  1991-03-05       Impact factor: 3.162

5.  Induction of expression of osteopontin (OPN; secreted phosphoprotein) in metastatic, ras-transformed NIH 3T3 cells.

Authors:  A F Chambers; E I Behrend; S M Wilson; D T Denhardt
Journal:  Anticancer Res       Date:  1992 Jan-Feb       Impact factor: 2.480

6.  Involvement of integrin alpha V gene expression in human melanoma tumorigenicity.

Authors:  B Felding-Habermann; B M Mueller; C A Romerdahl; D A Cheresh
Journal:  J Clin Invest       Date:  1992-06       Impact factor: 14.808

7.  Expression and distribution of osteopontin in human tissues: widespread association with luminal epithelial surfaces.

Authors:  L F Brown; B Berse; L Van de Water; A Papadopoulos-Sergiou; C A Perruzzi; E J Manseau; H F Dvorak; D R Senger
Journal:  Mol Biol Cell       Date:  1992-10       Impact factor: 4.138

8.  A secreted phosphoprotein marker for neoplastic transformation of both epithelial and fibroblastic cells.

Authors:  D R Senger; B B Asch; B D Smith; C A Perruzzi; H F Dvorak
Journal:  Nature       Date:  1983-04-21       Impact factor: 49.962

9.  Adhesion of metastatic, ras-transformed NIH 3T3 cells to osteopontin, fibronectin, and laminin.

Authors:  A F Chambers; C Hota; C W Prince
Journal:  Cancer Res       Date:  1993-02-01       Impact factor: 12.701

10.  Adhesive properties of osteopontin: regulation by a naturally occurring thrombin-cleavage in close proximity to the GRGDS cell-binding domain.

Authors:  D R Senger; C A Perruzzi; A Papadopoulos-Sergiou; L Van de Water
Journal:  Mol Biol Cell       Date:  1994-05       Impact factor: 4.138

View more
  91 in total

1.  Pre- and post-translational regulation of osteopontin in cancer.

Authors:  Pieter H Anborgh; Jennifer C Mutrie; Alan B Tuck; Ann F Chambers
Journal:  J Cell Commun Signal       Date:  2011-04-26       Impact factor: 5.782

2.  Matricellular proteins osteopontin and osteonectin/SPARC in pancreatic carcinoma.

Authors:  Anne M Delany
Journal:  Cancer Biol Ther       Date:  2010-07-01       Impact factor: 4.742

3.  Osteopontin is up-regulated and associated with neutrophil and macrophage infiltration in glioblastoma.

Authors:  Nadia A Atai; Manju Bansal; Cheungh Lo; Joost Bosman; Wikky Tigchelaar; Klazien S Bosch; Ard Jonker; Philip C De Witt Hamer; Dirk Troost; Christopher A McCulloch; Vincent Everts; Cornelis J F Van Noorden; Jaro Sodek
Journal:  Immunology       Date:  2010-08-17       Impact factor: 7.397

4.  Osteopontin expression in ductal adenocarcinomas and undifferentiated carcinomas of the pancreas.

Authors:  R Sedivy; K Peters; G Klöppel
Journal:  Virchows Arch       Date:  2004-11-26       Impact factor: 4.064

5.  Comparison of osteopontin expression in endometrioid endometrial cancer and ovarian endometrioid cancer.

Authors:  Yasunori Hashiguchi; Hiroshi Tsuda; Christina A Bandera; Sadako Nishimura; Takeshi Inoue; Naoki Kawamura; Ross S Berkowitz; Samuel C Mok
Journal:  Med Oncol       Date:  2006       Impact factor: 3.064

Review 6.  Receptor crosstalk: reprogramming B cell receptor signalling to an alternate pathway results in expression and secretion of the autoimmunity-associated cytokine, osteopontin.

Authors:  T L Rothstein; B Guo
Journal:  J Intern Med       Date:  2009-06       Impact factor: 8.989

7.  Osteopontin expression in proliferated bile ductules: the correlation with liver damage in fulminant hepatitis.

Authors:  Takuma Tajiri; Genshu Tate; Toshiaki Kunimura; Yutaka Endo; Kazuaki Inoue; Toshiyuki Mitsuya; Toshio Morohoshi; Makoto Yoshiba
Journal:  Dig Dis Sci       Date:  2005-01       Impact factor: 3.199

8.  Osteopontin expression in intratumoral astrocytes marks tumor progression in gliomas induced by prenatal exposure to N-ethyl-N-nitrosourea.

Authors:  Taichang Jang; Todd Savarese; Hoi Pang Low; Sunchin Kim; Hannes Vogel; David Lapointe; Timothy Duong; N Scott Litofsky; James M Weimann; Alonzo H Ross; Lawrence Recht
Journal:  Am J Pathol       Date:  2006-05       Impact factor: 4.307

9.  Reduction of elevated plasma osteopontin levels with resection of non-small-cell lung cancer.

Authors:  Justin D Blasberg; Harvey I Pass; Chandra M Goparaju; Raja M Flores; Suzie Lee; Jessica S Donington
Journal:  J Clin Oncol       Date:  2010-01-19       Impact factor: 44.544

10.  RNA aptamer blockade of osteopontin inhibits growth and metastasis of MDA-MB231 breast cancer cells.

Authors:  Zhiyong Mi; Hongtao Guo; M Benjamin Russell; Yingmiao Liu; Bruce A Sullenger; Paul C Kuo
Journal:  Mol Ther       Date:  2008-11-04       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.